Adicet completes prula-cel SLE study visits; topline due Sept 2026; ADI-212 IND cleared

Adicet Bio, Inc.

Prula-cel Phase 1 last patient visit completed; topline data from 22 SLE patients (13 with ≥12 mo follow-up) expected September 2026.
FDA cleared IND for ADI-212 in mCRPC; Phase 1 enrollment to start 4Q 2026.
Expanded prula-cel to outpatient setting after FDA alignment; systemic sclerosis update expected Q4 2026.
In vivo CAR-T platform: first candidate expected in clinic 2H 2027; programs target myeloma, NHL, solid tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.